{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-002039","form_type":"8-K","ticker":"IPSC","cik":"0001850119","company_name":"Century Therapeutics, Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.138488+00:00","generated_at":"2026-06-20T18:14:43.513084+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Century Therapeutics restructures pipeline, cuts headcount 25% to extend cash runway into 2026","bullets":["De-prioritizes CNTY-103 (glioblastoma) and discovery program; focuses on CNTY-101, CNTY-102, CNTY-107.","Reduces headcount by ~25%; closes labs in Seattle and Hamilton, consolidates research in Philadelphia.","Extends cash runway into 2026; Phase 1 CNTY-101 enrollment expected imminently; partnered BMS programs unaffected.","Hy Levitsky, President of R&D, resigns effective Jan 31, 2023; Luis Borges and Adrienne Farid assume responsibilities."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-002039","json":"https://secwatch.observer/filing/0001104659-23-002039.json","markdown":"https://secwatch.observer/filing/0001104659-23-002039.md","text":"https://secwatch.observer/filing/0001104659-23-002039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850119/000110465923002039/0001104659-23-002039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850119/000110465923002039/tm232470d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:14:43.513084+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}